I worked for him and also on the P2Y12 receptor antagonists. What I find impressive is that it is his own money that he pumps into it now as the new company is struggling to survive. However the company was stretched very thin in too many disease areas for the size, most of my friends lost their job in the last 6 months. Glad to see some news as the share price is very low currently.